Two trends: Global pricing and ‘Pharm-to-table’
EndPoints notes that the Most Favored Nation Executive Order has led some large pharmaceutical firms to make two changes: (i) start charging Europeans the same price as the US, and (ii) start selling more products direct to consumer (a.k.a. ‘pharm to table‘) AbbVie, Novartis and Boehringer Ingelheim each joined their peers in making price-related concessions…